Navigation Links
DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
Date:6/29/2009

a Phase 1 clinical trial in normal volunteers.

For further information regarding DOR BioPharma, Inc., please visit the Company's website at www.dorbiopharma.com.

This press release contains forward-looking statements that reflect DOR BioPharma, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec(R), particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its b
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
2. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
3. PDL BioPharma Announces Internal CEO Investigation Found No Credible Evidence of Improper Personal Conduct or Breach of Fiduciary Duty
4. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
5. PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
6. XTL Biopharmaceuticals Announces Presentation of Novel Pre-Clinical Inhibitors of Hepatitis C at an Upcoming International Scientific Conference
7. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
8. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
9. Keryx Biopharmaceuticals to Present at Bank of America Investment Conference
10. Morria Biopharmaceuticals Plc Announces Appointment of Dr. Rosemary Mazanet as Interim Chief Executive Officer
11. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2015)... April 30, 2015 According to ... Market by Product (Portable & Non-Portable), Component (Accelerometer, ... Automotive, Chemical, Metal & Mining, & Others), & ... market is expected to reach $1,453.76 Million by ... 71 market data tables and 92 figures spread ...
(Date:4/29/2015)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") today announced its results ... fiscal 2014 year-end financial statements and MD&A have been filed on SEDAR ... , 2014 , 2013 Revenue 3,968 , ... 1,326 , 1,703 , 2,231 , ... 3,377 , 4,562 Ebitda* 92 , 418 ...
(Date:4/29/2015)... , April 29, 2015 Cambrex Corporation (NYSE: ... be released on Friday, May 1, 2015 before the market ... The Company will host a conference call to discuss the ... When: , Friday, May 1, 2015 at ... , 1-888-468-2440 for U.S.1-719-325-2454 for International  Passcode:  7993632 Dial-in ...
(Date:4/29/2015)... April 29, 2015 The leading Regenerative ... that its regenerative stem cell therapy has processed more ... seeking to discover a successful treatment for horses with ... 2003 VetStem signed a worldwide exclusive license for adipose-derived ... the first horse was treated in January 2004. Shortly ...
Breaking Biology Technology:Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 2Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 3Vibration Monitoring Equipment (Portable & Non-Portable) Market worth $1,453.76 Million by 2020 - New Report by MarketsandMarkets 4Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4VetStem Biopharma -Regenerative Cell Therapy has processed over 11,000 samples 2
... April 28 Simcere,Pharmaceutical Group (NYSE: SCR ... pharmaceuticals and manufacturer of the patented,anti-cancer biotech product ... Suisse,s 3rd Annual Healthcare Trip, to be held ... and Weihai., Simcere senior management will give ...
... NEW YORK, April 28 Ever been so tired you ... That,s how Holly Jacobson, a nurse,in Clermont, Florida, felt every ... five boys under the age of nine. Nothing a good ... she began experiencing palpitations,breathlessness and fatigue whenever she played with ...
... Corporation,(Nasdaq: ACEL ) today announced that Kuslima Shogen, ... from the company on,or before March 31, 2009. The ... and Alfacell has been terminated., The termination of ... payments from the Company to Ms. Shogen by an ...
Cached Biology Technology:Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip 2D-Ribose Helps Energy-Starved Hearts 2Alfacell Announces Retirement of Chief Executive Officer 2Alfacell Announces Retirement of Chief Executive Officer 3Alfacell Announces Retirement of Chief Executive Officer 4
(Date:4/20/2015)... , April 20, 2015 The ... Glenbeigh Records Management (GRM), Ireland,s ... Dubai Islamic Bank. Having built up an impressive track record ... a leading player within the records management sector in ... to double is GCC staffbase and employ a further eight ...
(Date:4/13/2015)... 2015  higi, a leading cloud-based consumer engagement platform ... engage with their communities around health and wellness, announced ... secure API.  ... affordable, and convenient vehicle to receive validated health information ... The API will allow higi,s trusted partners, on ...
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... The SARS virus set alarm bells ringing across the world ... of the effectiveness of the treatments used against it has ... was commissioned by the World Health Organization and has been ... is caused by a virus; the main symptoms are pneumonia ...
... executed an exclusive license agreement for a next ... Inc. This innovative DNA-sequencing technology was invented by ... head of DNA Sequencing and Chemical Biology at ... at Columbia University. The fundamentals of this new ...
... diabetics, regenerating heart muscle after it fails, and improving ... list of 10 potential breakthroughs for health in developing ... medicine, according to a study published today in the ... Conducted by University of Toronto researchers (from the McLaughlin ...
Cached Biology News:SARS: No evidence that any of the treatments worked 2SARS: No evidence that any of the treatments worked 3SARS: No evidence that any of the treatments worked 4SARS: No evidence that any of the treatments worked 5Columbia University licenses next-generation DNA sequencing technology 2Replacing insulin is top-ranked breakthrough foreseen for health in developing world 2Replacing insulin is top-ranked breakthrough foreseen for health in developing world 3Replacing insulin is top-ranked breakthrough foreseen for health in developing world 4Replacing insulin is top-ranked breakthrough foreseen for health in developing world 5Replacing insulin is top-ranked breakthrough foreseen for health in developing world 6
... a direct antibiotic-based selection system for recombinant ... survival, eliminating the need for costly color ... close to 100% accuracy in recombinant selection. ... robot colony picking. This cloning kit can ...
Mouse monoclonal [H4B4] to LAMP2 - Lysosome Marker (Phycoerythrin) ( Abpromise for all tested applications). entrezGeneID: 3920 SwissProtID: P13473...
... thermal cycler is a dual-bay expansion for ... operated independently, using a PC. The Dyad ... units (sample-holder, heat-pump assemblies), which hold different ... real-time detector. Peltier heat pumps provide exceptional ...
... PCR plate, Directly compatible with ABI thermal ... for improved sealing characteristics can be ... or cap strips, Certified free of DNase, ... part of Thermo Fisher Scientific, the world ...
Biology Products: